PLA2G7 and thrombophilia: Switch to INSTI from PI, NNRTI or enfuvirtide has been associated with a reduction in the levels of biomarkers of inflammation, insulin resistance and hypercoagulability.63–66 Likewise, treatment initiation with EVG/CBT versus EFV was associated with greater declines in hsCRP, sCD14 and Lp-PLA2.67 Of note, previous studies comparing biomarker changes with NNRTI versus INSTI primarily included EFV, whereas the predominant NNRTI administered in our cohort was RPV.